In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Intellia Therapeutics Inc (NASDAQ: NTLA) closed the day trading at $9.73 down -3.13% from the previous closing price of $10.05. In other words, the price has decreased by -$3.13 from its previous closing price. On the day, 3.17 million shares were traded. NTLA stock price reached its highest trading level at $10.39 during the session, while it also had its lowest trading level at $9.585.
Ratios:
For a better understanding of NTLA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.73 and its Current Ratio is at 6.73. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 03 ’25 when Dube Michael P sold 1,372 shares for $12.18 per share. The transaction valued at 16,711 led to the insider holds 45,640 shares of the business.
BASTA JAMES sold 7,074 shares of NTLA for $86,161 on Jan 03 ’25. The EVP, General Counsel now owns 74,497 shares after completing the transaction at $12.18 per share. On Jan 03 ’25, another insider, Lebwohl David, who serves as the EVP, Chief Medical Officer of the company, sold 9,557 shares for $12.18 each. As a result, the insider received 116,404 and left with 87,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 991499968 and an Enterprise Value of 435004864. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.01 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 10.096 whereas that against EBITDA is -0.825.
Stock Price History:
The Beta on a monthly basis for NTLA is 1.83, which has changed by -0.60955715 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $34.87, while it has fallen to a 52-week low of $9.65. The 50-Day Moving Average of the stock is -29.09%, while the 200-Day Moving Average is calculated to be -52.44%.
Shares Statistics:
Over the past 3-months, NTLA traded about 2.82M shares per day on average, while over the past 10 days, NTLA traded about 3181960 shares per day. A total of 101.80M shares are outstanding, with a floating share count of 99.79M. Insiders hold about 2.02% of the company’s shares, while institutions hold 92.46% stake in the company. Shares short for NTLA as of 1735603200 were 21668143 with a Short Ratio of 7.69, compared to 1732838400 on 18914793. Therefore, it implies a Short% of Shares Outstanding of 21668143 and a Short% of Float of 24.229999.
